Tacrolimus with mini-methotrexate as prophylaxis for graft-versus-host disease in pediatric patients after allogeneic peripheral blood stem cell transplant or bone marrow transplant

J Pediatr Hematol Oncol. 2008 Dec;30(12):945-9. doi: 10.1097/MPH.0b013e318180bc31.

Abstract

Experience with tacrolimus in combination with mini-methotrexate to prevent graft-versus-host disease (GVHD) is limited in pediatric patients undergoing allogeneic blood or bone marrow transplants. We reviewed our use of this regimen in 24 pediatric patients who had 26 blood or marrow transplants. Acute GVHD occurred in 7 patients (4 unrelated donor transplants, 3 matched sibling transplants; 5 grade I to II, 1 grade III, and 1 not classifiable). One patient had extensive chronic GVHD (matched sibling transplant). In our experience, tacrolimus with mini-methotrexate has been well tolerated with minimal toxicity.

MeSH terms

  • Adolescent
  • Bone Marrow Transplantation*
  • Child
  • Child, Preschool
  • Drug Therapy, Combination
  • Female
  • Graft vs Host Disease / drug therapy
  • Graft vs Host Disease / prevention & control*
  • Hematologic Neoplasms / therapy*
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Infant
  • Male
  • Methotrexate / therapeutic use*
  • Neoplasm Recurrence, Local / diagnosis
  • Neoplasm Recurrence, Local / drug therapy
  • Peripheral Blood Stem Cell Transplantation*
  • Retrospective Studies
  • Survival Rate
  • Tacrolimus / therapeutic use*
  • Transplantation, Homologous
  • Treatment Outcome
  • Young Adult

Substances

  • Immunosuppressive Agents
  • Tacrolimus
  • Methotrexate